Final Verdict: 7 Clinical Facts Ozempic is not licensed for weight loss in the UK Wegovy is the licensed semaglutide weight management product Mounjaro and Wegovy are different drugs tirzepatide (dual GLP-1/GIP) vs semaglutide (GLP-1 only) In the SURMOUNT-5 head-to-head trial, Mounjaro produced 20.2% vs Wegovys 13.7% average weight loss Wegovy is approximately 75/month cheaper at Slinic maintenance doses important for cost-sensitive patients Wegovy has the NICE cardiovascular indication (April 2026) Mounjaro does not yet have this label Wegovy now has a licensed oral version (MHRA June 2026) Mounjaro does not yet have an oral equivalent Neither Ozempic off-label nor compounded alternatives are appropriate when licensed products are readily available from a GPhC-registered UK pharmacy Slinic prescribes Mounjaro and Wegovy both correctly licensed, both from Eli Lilly and Novo Nordisk authorised supply chains, both reviewed by a registered UK prescriber
And we follow this along
FDA bans compounded weight loss drugs this month This month, the window open to an era when compounded versions of glucagon-like peptide 1 (GLP-1) weight loss medications became available is expected to close
Semaglutide itself has a mildly bitter taste
Retatrutide is getting serious attention as a next-generation weight loss drug
Because NAION can occur in people with diabetes, hypertension, sleep apnea, and other vascular conditions, each case typically requires an individualized review of the patients medical history and risk factors
